Serum MMP-2 in acute phase emerges as a promising biomarker: its level correlates with the recurrence of cerebral amyloid angiopathy/intracerebral hemorrhage, which helps to evaluate the risk of cognitive impairment [256]. The gene discussed is MMP2; the disease is cerebral amyloid angiopathy.